Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroshi Ureshino

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
International Journal of Hematology|March 2, 2021
Treatment-free remission and immunity in chronic myeloid leukemiaHiroshi Ureshino
Expert Review of Hematology|January 7, 2026
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemiaHiroshi Ureshino, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|November 7, 2024
Efficacy and Safety of the First-in-Class STAMP-Inhibitor Asciminib in Patients With Chronic Myeloid LeukemiaHiroshi Ureshino, Shinya Kimura
Internal Medicine (Tokyo, Japan)|August 6, 2025
Low Generic Drug Penetration for Expensive Oral Molecular Targeted Agents: An Experience with Generic Imatinib in JapanKeisuke Kidoguchi, Hiroshi Ureshino, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2019
Mogamulizumab for the Treatment of Adult T-cell Leukemia/LymphomaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid LeukemiaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|August 10, 2020
Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid LeukemiaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Leukemia Research|November 26, 2019
Role of cancer immunology in chronic myelogenous leukemiaHiroshi Ureshino, Takero Shindo, Shinya Kimura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 10, 2017
Chronic myeloid leukemia and NK cell immunityHiroshi Ureshino, Takero Shindo, Hidenori Tanaka, et al.
Ejhaem|December 18, 2024
IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CPHiroshi Ureshino, Kazuharu Kamachi, Keisuke Kidoguchi, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
International Journal of Hematology|March 2, 2021
Treatment-free remission and immunity in chronic myeloid leukemiaHiroshi Ureshino
Expert Review of Hematology|January 7, 2026
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemiaHiroshi Ureshino, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|November 7, 2024
Efficacy and Safety of the First-in-Class STAMP-Inhibitor Asciminib in Patients With Chronic Myeloid LeukemiaHiroshi Ureshino, Shinya Kimura
Internal Medicine (Tokyo, Japan)|August 6, 2025
Low Generic Drug Penetration for Expensive Oral Molecular Targeted Agents: An Experience with Generic Imatinib in JapanKeisuke Kidoguchi, Hiroshi Ureshino, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2019
Mogamulizumab for the Treatment of Adult T-cell Leukemia/LymphomaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid LeukemiaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Clinical Lymphoma, Myeloma & Leukemia|August 10, 2020
Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid LeukemiaHiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Leukemia Research|November 26, 2019
Role of cancer immunology in chronic myelogenous leukemiaHiroshi Ureshino, Takero Shindo, Shinya Kimura
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 10, 2017
Chronic myeloid leukemia and NK cell immunityHiroshi Ureshino, Takero Shindo, Hidenori Tanaka, et al.
Ejhaem|December 18, 2024
IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CPHiroshi Ureshino, Kazuharu Kamachi, Keisuke Kidoguchi, et al.
Pageof 7